Evaluating the Safety and Satisfaction of HYAcorp MLF2 for Noninvasive Buttock Augmentation: A Multicenter Study
The increasing demand for noninvasive gluteal augmentation using hyaluronic acid (HA) gel highlights the need for research into its safety and effectiveness. This study aimed to assess the safety and satisfaction levels of patients and physicians regarding HA body filler for buttock enhancement. It...
Gespeichert in:
Veröffentlicht in: | Plastic and reconstructive surgery. Global open 2025-01, Vol.13 (1), p.e6415 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The increasing demand for noninvasive gluteal augmentation using hyaluronic acid (HA) gel highlights the need for research into its safety and effectiveness. This study aimed to assess the safety and satisfaction levels of patients and physicians regarding HA body filler for buttock enhancement. It also explores variations in outcomes across different injection sites and among different practitioners.
This retrospective, observational, descriptive multicenter study analyzed the outcomes of using a body HA filler (HYAcorp MLF2) for buttock augmentation across 4 Italian centers, with a 6-month follow-up period. Patients' and physicians' satisfaction levels were measured immediately postprocedure, and adverse events were monitored throughout the study period.
Thirty-five subjects received injections, with an average volume of 85.1 ± 42.2 mL per subject injected. Throughout follow-up, 94% of patients and 100% of physicians rated the improvement as "very good" or "good." Adverse events were generally mild-to-moderate, typically resolving within 2-7 days. The most frequently recorded adverse effects were swelling, pain, and redness. No significant differences were observed among injectors (
> 0.05).
HYAcorp MLF2 is safe and effective for buttock augmentation, demonstrated by high satisfaction rates and manageable, mild-to-moderate adverse events, with no significant variation based on practitioner experience or clinic site. |
---|---|
ISSN: | 2169-7574 2169-7574 |
DOI: | 10.1097/GOX.0000000000006415 |